Alethia Biotherapeutics Inc.
Founded 2002 · 12 employees on LinkedIn · 2 known investors
Alethia Biotherapeutics is a clinical-stage biotechnology company developing cancer treatments that target tumor resistance by inhibiting the epithelial-mesenchymal transition (EMT) and remodeling the immunosuppressive tumor microenvironment. Its lead asset, sotevtamab, is a monoclonal antibody intended to be combined with standard therapies across multiple cancer indications.
Investors · 2
Frequently asked questions
- What does Alethia Biotherapeutics Inc. do?
- Alethia Biotherapeutics is a clinical-stage biotechnology company developing cancer treatments that target tumor resistance by inhibiting the epithelial-mesenchymal transition (EMT) and remodeling the immunosuppressive tumor microenvironment. Its lead asset, sotevtamab, is a monoclonal antibody intended to be combined with standard therapies across multiple cancer indications.
- Who are Alethia Biotherapeutics Inc.'s investors?
- Alethia Biotherapeutics Inc.'s investors include BDC Fund Investments (Fund-of-Funds), BDC Venture Capital.